Observational studies suggest that vitamin D supplementation is associated with benefits for knee osteoarthritis, but current trial evidence is contradictory.
RESULTS
Of 413 enrolled participants (mean age, 63.2 years; 50% women), 340 (82.3%) completed the study. The level of 25-hydroxyvitamin D increased more in the vitamin D group (40.6 nmol/L) than in the placebo group (6.7 nmol/L) (P < .001) over 2 years. There were no significant differences in annual change of tibial cartilage volume or WOMAC pain score. There were no significant differences in change of tibiofemoral cartilage defects or change in tibiofemoral bone marrow lesions. Adverse events (Ն1 per patient) occurred in 56 participants in the vitamin D group and in 37 participants in the placebo group (P = .04). disease-modifying therapies for osteoarthritis; therefore, there is a need to develop cost-effective approaches to prevent the development and progression of osteoarthritis. Vitamin D can reduce bone turnover and cartilage degradation, thus potentially preventing the development and progression of knee osteoarthritis. 4, 5 Epidemiological studies
showed that low serum 25-hydroxyvitamin D levels were associated with greater knee pain, 6 ,7 a higher prevalence of radiographic knee osteoarthritis, 8 and higher risk of progression. 9, 10 However, observational studies are subject to inherent bias and confounding factors such as physical activity and sun exposure. 11 In addition, 2 small existing randomized controlled trials (RCTs) reported contradictory results. 5, 12 The inconsistencies are likely because of variations in inclusion criteria, outcome measures, follow-up time, and sample size. 13 An updated systematic review called for further larger welldesigned RCTs to determine whether vitamin D supplementation can slow disease progression. 14 Therefore, we conducted an RCT of participants with clinically relevant inclusion criteria, 13 to evaluate the effects of 2 years of vitamin D supplementation vs placebo on knee pain and knee cartilage volume in patients with symptomatic knee osteoarthritis combined with low 25-hydroxyvitamin D levels. Effects on other knee structural abnormalities, including cartilage defects and bone marrow lesions, were also assessed.
Methods

Trial Design
The Vitamin D Effect on Osteoarthritis (VIDEO) study was a randomized, double-blind, placebo-controlled trial, which was conducted between June 2010 and December 2013. 15 Participants were recruited from June 2010 to December 2011 in Tasmania and Victoria, Australia, through advertisements in local media and community groups, as well as referrals from general practitioners, rheumatologists, and orthopedic surgeons. A telephone prescreening was conducted to inquire about knee pain status, comorbidities, participation in other studies, and whether the survey recipient anticipated knee or hip surgery within next 2 years. Potentially eligible participants were subsequently assessed during a clinic visit that included a physical examination, knee radiography, and assessment of serum 25-hydroxyvitamin D levels. The trial protocol appears in Supplement 1.
Participants
Inclusion and exclusion criteria were described in the published protocol. 15 The knee that met the previously described inclusion and exclusion criteria was selected as the study knee for outcome measures. When both knees met the criteria, the study knee was defined as the one with worse pain assessed using the visual analog scale.
Randomization and Masking
Participants were allocated to either the vitamin D or placebo group at a ratio of 1:1 based on computer-generated random numbers. Allocation concealment was confirmed by a central automated allocation procedure that was independent of the investigators. Treatment assignment was masked from all participants, research coordinators, and investigators and maintained until all data were collected, confirmed for accuracy, and cleaned, and statistical analyses were performed.
Interventions
Participants in the treatment group were given a monthly capsule of 50 000 IU (1.25 mg) of vitamin D 3 (cholecalciferol) for 24 months (Nationwide Compounding Pharmacy).
18 Participants in the control group received an identical inert placebo provided by the same company.
Outcomes
Knee pain was added as an additional primary end point to the protocol on June 6, 2012, after comments were received from reviewers of the methods article. 15 The secondary outcomes included on clinicaltrials.gov slightly differ from the published protocol because several outcome measures were added in the substudies as secondary outcomes on clinicaltrial.gov, whereas the osteoarthritis outcomes were the focus in the published protocol. 
Assessment of Pain
Knee pain was assessed at baseline and at months 3, 6, 12, and 24. Five items of WOMAC pain scale in 100-mm visual analog format were used to assess pain during walking, using stairs, in bed, sitting or lying, and standing. Items were summed to create a total pain score (range, 0-500). 20 Knee pain in most days of the previous month was assessed using a 100-mm visual analog scale.
Explanation of WOMAC Scoring
The total WOMAC score indicates the sum of subscale scores including pain, stiffness, and physical function. Missing responses were managed according to the WOMAC user guide. 21 The WOMAC pain score was considered void if more than 1 item was missing. In the event of a missing item, the remaining 4 items were averaged and then multiplied by 5.
OMERACT-OARSI Responder Criteria
The OARSI Standing Committee for Clinical Trials Response Criteria Initiative developed a set of responder criteria (OMERACT-OARSI) to categorize individual response to treatment as a single variable for clinical trials. 22 Response using the exact OMERACT-OARSI criteria could not be directly evaluated because patient global assessment was not recorded in this trial; therefore, we used a modified OMERACT-OARSI responder definition without patient global assessment. OMERACT-OARSI responders in this study were defined as participants with (1) at least 50% improvement and an absolute change of at least 20 points in the mean WOMAC pain score or mean WOMAC function score; or (2) at least 20% improvement and an absolute change of at least 10 points in both the mean WOMAC pain score and the mean WOMAC function score.
MRI Assessment of Knee Structural Changes
MRI scans of the study knee were obtained according to a standardized protocol using a 1.5 T whole-body MRI unit with a commercial transmit-receive extremity coil. The sequences used for cartilage volume assessment were sagittal fat saturated (FS) T1-weighted spoiled gradient echo (GRE). Cartilage defects and bone marrow lesions were assessed using T2-weighted/proton density-weighted fast spin echo (FSE) sequences. MRIs were assessed by trained readers blinded to treatment allocation according to methods described previously.
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Cartilage Volume | Cartilage volume was determined using the previously described image processing techniques. 8 The volumes of individual cartilage plates (medial tibial and lateral tibial) were isolated by manually drawing disarticulation contours around the cartilage boundaries on a section-bysection basis then resampled by means of bilinear and cubic interpolation for final 3-dimensional rendering using OsiriX Lite imaging software (32-bit version 5.9, Pixmeo SARL). The coefficient of variation was 2.1% for medial tibia and 2.2% for lateral tibia. 23 Cartilage Defects | Cartilage defects (0-4) were graded on T2-weighted images using a modified Outerbridge classification 24 at medial tibial, medial femoral, lateral tibial, and lateral femoral sites (described in the protocol). 15 A total score was calculated as the total of subregional scores. Intraobserver reliability expressed as an intraclass correlation coefficient ranged from 0.77 to 0.94.
Bone Marrow Lesions | Bone marrow lesions, defined as discrete areas of increased signal adjacent to the subcortical bone, were measured using a modified Whole-Organ Magnetic Resonance Imaging Score (0 = none, 1 ≤ 25% of the subregion, 2 = 25%-50%, and 3 ≥ 50%). 25 A total score of the tibiofemoral compartment was calculated as the total of 13 subregional scores (0-39). The intraclass correlation coefficient of this bone marrow lesion ranged from 0.93 to 0.98.
25-Hydroxyvitamin D Assays
Serum 25-hydroxyvitamin D was assayed at screening, month 3, and month 24 using direct competitive chemiluminescent immunoassays (DiaSorin Inc). The intraassay and interassay coefficients of variation were 3.2% and 6.0%.
Sample Size
Quantification of cartilage volume loss has been used to monitor the progression of knee osteoarthritis. 26 Previous studies reported that mean annual loss of medial tibial cartilage volume loss in patients with knee osteoarthritis was 4.5%. 27 Monthly intake of 50 000 IU of vitamin D would achieve serum 25-hydroxyvitamin D levels greater than 60 nmol/L 28 and this change was estimated to lead to an absolute reduction in medial tibial cartilage loss of 2.2% annually, 8 which was expected to translate into a risk reduction of 44% for total knee replacement over 4 years. 29 Sample size calculation assumed α = .05 and β = .20 and was performed based on the Cohen formula. 30 We calculated that 400 participants at baseline (200 in each group), allowing 20% for dropouts, would have at least 80% power to detect a 2.2% between-group difference in medial tibial cartilage loss. For change in WOMAC pain, we anticipated a standard deviation of 70.5 on a score from 0 to 500. 12 With 400 partici-
Statistical Analysis
WOMAC and visual analog scale knee pain scores were analyzed using a repeated-measures mixed model with terms for age, sex, body mass index (calculated as weight in kilograms divided by height in meters squared), treatment, month, and trial center. The correlation within the repeated measures was addressed by using an individual participant identification as a random effect. The effect of treatment was evaluated by the month × treatment interaction. In a post hoc analysis, the proportion of participants who achieved at least 20% and 50% improvement in WOMAC pain score was evaluated, which has been shown to be clinically relevant. 31 The independent t test was used to compare annual changes in cartilage volume and absolute changes of cartilage defects and bone marrow lesions between groups. An increase in cartilage defects and bone marrow lesions was defined as a change of more than 1 unit in score. Presence of an increase in cartilage defects or bone marrow lesions was compared between the 2 groups using logistic regression.
Both intention-to-treat and per-protocol analyses were used. Per-protocol analysis was defined as achieving a 25-hydroxyvitamin D level of greater than 60 nmol/L at the month 3 visit. Multiple imputation by chained equations was used to address missing data caused by loss to follow-up and nonresponses. Imputations were performed separately for each treatment group and each outcome using baseline values, age, sex, body mass index, and serum 25-hydroxyvitamin D level. All statistical analyses were performed using Stata version 13.0 (Stata Corporation) and a 2-sided P value of .05 was considered statistically significant. Figure 1 shows the flow of study participants. A total of 599 participants were screened for eligibility from June 5, 2010, to December 1, 2011, and 413 participants were randomly assigned to receive either vitamin D (n = 209) or placebo (n = 204). The mean age of participants was 63.2 years, 208 (50%) were women, and mean body mass index was 29.6. Participants' demographic characteristics were comparable at baseline between 2 groups ( Table 1) . Seventy-three participants withdrew from the study (28 [13.4%] in the vitamin D group and 45 [22.1%] in the placebo group [P = .02]) and 340 participants (82.3%) completed the trial. There were no significant differences between participants who completed the study vs those who did not, except that among those who withdrew, more were women and had lower tibial cartilage volume (eTable in Supplement 2). Fewer participants discontinued treatment in the vitamin D group (8) than the placebo 
Results
Participants
Secondary End Points
The results for tibiofemoral cartilage defects and bone marrow lesions are shown in Table 2 . The difference in cartilage defect score was not different between groups. Bone marrow lesion scores decreased in both groups and no significant difference was observed.
Post Hoc Analyses
In post hoc analyses (Table 2) , participants in the vitamin D group had statistically significant improvements in visual analog scale knee pain ( Figure 2E ) scores when compared with the placebo group. The vitamin D group had more improvement in the total WOMAC score ( Figure 2B ) and WOMAC function ( Figure 2C ) but not WOMAC stiffness ( Figure 2D ). There were 115 (64%) participants in the vitamin D group and 95 (57%) participants in the placebo group (P = .16) who achieved a 20% improvement in WOMAC knee pain score over 2 years. There were 90 (50%) participants in the vitamin D group and 65 (39%) participants in the placebo group (P = .04) who showed at least a 50% improvement in WOMAC pain score. brittle bones, and kidney dysfunction) vs none in the placebo group. There was 1 episode of renal calculus in each group.
Discussion
The purpose of this RCT was to determine whether vitamin D supplementation could reduce knee pain and cartilage loss and also prevent progression of other knee structural abnormalities in patients with knee osteoarthritis and low 25-hydroxyvitamin D levels. Results showed that even among study participants with low 25-hydroxyvitamin D, supplementation did not slow cartilage loss or improve WOMAC-assessed pain. These data suggest a lack of evidence to support vitamin D supplementation for slowing disease progression or structural change in knee osteoarthritis. The first study included patients without vitamin D deficiency who may not benefit from vitamin D supplementation and patients whose disease was too severe to respond to vitamin D treatment. Also, it had a small sample size (146 participants). 13 The second study did not examine structural changes and had a 1-year follow-up, which may be too short to observe disease progression. 33 Our study addressed these limitations by recruiting patients without severe knee osteoarthritis with low 25-hydroxyvitamin D levels and provided follow-up for 2 years. Nonetheless, our results are largely consistent with the prior 2 trials.
Structural changes in cartilage and noncartilaginous joint tissue assessed using MRI, are now recommended outcomes for clinical trials in osteoarthritis. 34 An observational study showed that lower serum 25-hydroxyvitamin D levels were associated with greater cartilage volume loss over 2.7 years. 8 In the current study, the amount of tibial cartilage volume loss in the placebo group is consistent with the findings of a previous RCT. 5 We did not find significant effects on change in knee cartilage defects and bone marrow lesions.
Adverse effects of vitamin D use may include hypercalcemia. Although intermittent use of very high-dose vitamin D (eg, 500 000 IU/year) may not be safe, 35 our study suggests that a monthly regimen at a dosage of 50 000 IU is safe in elderly patients, even though the serum 25-hydroxyvitamin D levels of long-term users are at the upper limit of the normal range.
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The key strength of this RCT is the inclusion and exclusion criteria. This study included only adult patients with knee osteoarthritis who had a vitamin D insufficiency-patients who may be the most likely to benefit from vitamin D supplements. We also used a predefined range of knee pain to prevent a ceiling or floor effect in the statistical analyses. Patients with late-stage knee osteoarthritis were excluded because of very little cartilage remaining; thus, any possible benefits of therapy on cartilage would be difficult to identify. By using these criteria, we studied a patient population in whom the likelihood of demonstrating an effect (if truly present) of vitamin D supplementation was maximized.
This study also had limitations. First, WOMAC pain as a second primary outcome was added during the recruitment period at the time the protocol was published. However, this change was made before the trial was completed, before any data analyses, and the original sample size had sufficient power to detect the expected difference in WOMAC pain. Second, loss to follow-up was 17.7% and was less in the vitamin D group (28 participants) than in the placebo group (45 participants) (P = .02). There were fewer participants who withdrew from their assigned intervention in the vitamin D group (n = 8) than in the placebo group (n = 21). Participants who did not adhere to their assigned intervention could be expected to have a worse outcome than those who did. Although this could bias the result toward the null, similar results were seen in per-protocol analysis, suggesting the differential dropout rate had minimal effects on our results. Last, this study did not prespecify clinical outcomes such as visual analog scale knee pain and WOMAC physical function as primary or secondary end points.
Conclusions
Among patients with symptomatic knee osteoarthritis and low serum 25-hydroxyvitamin D levels, vitamin D supplementation, when compared with placebo, did not result in significant differences in change in MRI-measured tibial cartilage volume or change in WOMAC knee pain score over 2 years. These findings do not support the use of vitamin D supplementation for preventing tibial cartilage loss or improving WOMAC knee pain among patients with knee osteoarthritis. a Two participants were admitted to the hospital after a fall and 1 was admitted because of severe diarrhea. b Includes headache, lethargy, flu symptoms, and other events (neuroma, dysphonia, hypotension, lipoma, hypersensitivity, and Sjögren syndrome).
